National Cancer Center Hospital, Gastrointestinal Medical Oncology Division, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Anticancer Res. 2014 Feb;34(2):1053-6.
Typically, bevacizumab is initially infused for 90 min, then for 60 min, and subsequently for 30 min. The objective of the present study was to evaluate the safety profile of a short infusion of bevacizumab in Japanese colorectal cancer patients.
The records of 58 patients who received bevacizumab (5 mg/kg) from June 2010 to September 2010 were reviewed. Bevacizumab was administered for 30 min at the first time. If patients had no infusion reaction, the infusion time was shortened to 10 min.
None of the 58 patients who received bevacizumab experienced an infusion reaction (95% confidence interval 0-6.2). The only serious adverse event related to bevacizumab infusion was grade 3 proteinuria in 2 patients.
Short infusion of bevacizumab for 30 min the first time and 10 min is safe and feasible.
通常情况下，贝伐珠单抗的初始输注时间为 90 分钟，然后是 60 分钟，随后是 30 分钟。本研究的目的是评估贝伐珠单抗在日本结直肠癌患者中的短期输注的安全性。
回顾了 2010 年 6 月至 2010 年 9 月期间接受贝伐珠单抗（5mg/kg）治疗的 58 例患者的记录。首次给予贝伐珠单抗输注 30 分钟。如果患者没有输注反应，则将输注时间缩短至 10 分钟。
接受贝伐珠单抗治疗的 58 例患者均未发生输注反应（95%置信区间 0-6.2）。唯一与贝伐珠单抗输注相关的严重不良事件是 2 例患者发生 3 级蛋白尿。
首次输注贝伐珠单抗 30 分钟，然后输注 10 分钟是安全且可行的。
Zotero 插件